Literature DB >> 12361242

Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.

John Carl Panetta1, Mark Wilkinson, Ching-Hon Pui, Mary V Relling.   

Abstract

Etoposide is used to treat childhood malignancies, and its plasma pharmacokinetics have been related to pharmacodynamic endpoints. Limiting the number of samples should facilitate the assessment of etoposide pharmacokinetics in children. We compared limited sampling strategies using multiple linear regression of plasma concentrations and clearance with Bayesian methods of estimating clearance using compartmental pharmacokinetic models. Optimal sampling times were estimated in the multiple linear regression method by determining the combination of two samples which maximized the correlation coefficient, and in the Bayesian estimation approach by minimizing the variance in estimates of clearance. Clearance estimates were compared to the actual clearances from Monte Carlo-simulated data and predicted clearances estimated using all available plasma concentrations in clinical data from children with acute lymphoblastic leukemia. Multiple linear regression poorly predicted clearance (mean bias 8.3%, precision 17.5%), but improved if plasma concentrations were logarithmically transformed (mean bias 1.4%, precision 12.5%). Bayesian estimation methods with optimal samples gave the best overall prediction (mean bias 2.5%, precision 6.8%) and also performed better than regression methods for abnormally high or low clearances. We conclude that Bayesian estimation with limited sampling gives the best estimates of etoposide clearance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361242     DOI: 10.1023/a:1019755608555

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  20 in total

1.  Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.

Authors:  I Mahmood; R Miller
Journal:  Int J Clin Pharmacol Ther       Date:  1999-09       Impact factor: 1.366

2.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

3.  Optimal experiment design for nonlinear models subject to large prior uncertainties.

Authors:  E Walter; L Pronzato
Journal:  Am J Physiol       Date:  1987-09

4.  Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection.

Authors:  X Cai; M H Woo; M J Edick; M V Relling
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-05-28

5.  A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.

Authors:  B Tranchand; C Amsellem; E Chatelut; G Freyer; A Iliadis; B Ligneau; V Trillet-Lenoir; P Canal; I Lochon; C J Ardiet
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

6.  A limited sampling model for the pharmacokinetics of etoposide given orally.

Authors:  D Gentili; M Zucchetti; V Torri; C Sessa; J de Jong; F Cavalli; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Limited sampling models for reliable estimation of etoposide area under the curve.

Authors:  J B Holz; H Köppler; L Schmidt; H W Fritsch; K H Pflüger; H Jungclas
Journal:  Eur J Cancer       Date:  1995-10       Impact factor: 9.162

8.  Investigation of the variability of etoposide pharmacokinetics in children.

Authors:  J Boos; E Real; J Wolff; T Euting; H Jürgens
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-11

9.  Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.

Authors:  D S Sonnichsen; R C Ribeiro; X Luo; P Mathew; M V Relling
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

10.  Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.

Authors:  B Desoize; F Marechal; A Cattan
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

View more
  7 in total

Review 1.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

4.  Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.

Authors:  Nobuko Hijiya; John C Panetta; Yinmei Zhou; Emily P Kyzer; Scott C Howard; Sima Jeha; Bassem I Razzouk; Raul C Ribeiro; Jeffrey E Rubnitz; Melissa M Hudson; John T Sandlund; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

Review 5.  A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.

Authors:  Gabriel W Loh; Lillian S L Ting; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.

Authors:  Eva Santamaría; Javier Alejandro Estévez; Jordi Riba; Iñaki Izquierdo; Marta Valle
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

7.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.